Revenue → Gross profit: $14.5BPharmaceutical → Revenue: $13.9BMedical devices → Revenue: $8.0BRevenue → Cost of revenue: $7.4BOther → Net profit: $7.3BGross profit → Operating profit: $6.2BOncology → Pharmaceutical: $5.7BGross profit → SG&A: $5.1BImmunology → Pharmaceutical: $3.7BOperating profit → Net profit: $3.5BGross profit → R&D: $3.2BOperating profit → Tax: $2.6BSurgery → Medical devices: $2.4BOrthopaedics → Medical devices: $2.2BCardiovascular → Medical devices: $2.1BNeuroscience → Pharmaceutical: $1.6BVision → Medical devices: $1.3BPulmonary → Pharmaceutical: $1.0BOther pharma → Pharmaceutical: $1.0BInfectious diseases → Pharmaceutical: $0.8BInterest → Net profit: $0.1BGross profit → Restructuring: $0.0BCardiovascular$2.1B16% Y/YCost of revenue$7.4B13% Y/YGross profit$14.5B-2% Y/YImmunology$3.7BInfectious diseases$0.8BInterest$0.1BMedical devices$8.0B3% Y/YNet profit$11.0B119% Y/YNeuroscience$1.6BOncology$5.7BOperating profit$6.2B5% Y/YOrthopaedics$2.2BOther$7.3BOther pharma$1.0BPharmaceutical$13.9B2% Y/YPulmonary$1.0BR&D$3.2B-9% Y/YRestructuring$17M-90% Y/YRevenue$21.9B2% Y/YSG&A$5.1B-3% Y/YSurgery$2.4BTax$2.6B142% Y/YVision$1.3BJohnson & Johnson Q1 FY25 Income Statementcreated with SankeyArt.com
2022
Q4 Full Year
2023
Q1 Q2 Q3 Q4 Full Year
2024
Q1 Q2 Q3
2025
Q1
Copy and edit diagram